Pacific Biosciences Of California (PACB) Gains from Investment Securities (2022 - 2025)

Pacific Biosciences Of California's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$18.7 million for Q1 2025.

• On a quarterly basis, Gains from Investment Securities fell 26614.29% year-over-year to -$18.7 million in Q1 2025; TTM through Dec 2025 was -$18.7 million, a 2100.0% decrease from a year earlier, with the FY2025 full-year figure at -$18.7 million, down 2100.0% from the prior year.
• Gains from Investment Securities eased to -$18.7 million in Q1 2025 per PACB's latest filing, from -$2.0 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $12.3 million in Q1 2023 and bottomed at -$18.7 million in Q1 2025.
• The 4-year median for Gains from Investment Securities is $515000.0 (2023), against an average of -$176083.3.
• Across the five-year window, Gains from Investment Securities surged 1252.96% in 2023 and plunged 26614.29% in 2025, its largest moves.
• Year by year, Gains from Investment Securities stood at $4.6 million in 2022, then slumped by 76.08% to $1.1 million in 2023, then plunged by 277.27% to -$2.0 million in 2024, then sank by 858.97% to -$18.7 million in 2025.
• Per Business Quant, the three latest PACB Gains from Investment Securities figures stand at -$18.7 million (Q1 2025), -$2.0 million (Q4 2024), and $1.2 million (Q3 2024).